-
Something wrong with this record ?
Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination
G. Hanquet, P. Krizova, P. Valentiner-Branth, SN. Ladhani, JP. Nuorti, A. Lepoutre, J. Mereckiene, M. Knol, BA. Winje, P. Ciruela, M. Ordobas, M. Guevara, E. McDonald, E. Morfeldt, J. Kozakova, HC. Slotved, NK. Fry, H. Rinta-Kokko, E. Varon, M....
Language English Country Great Britain
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 1946-03-01 to 6 months ago
Open Access Digital Library
from 1946-03-01
Health & Medicine (ProQuest)
from 1946-03-01 to 6 months ago
- MeSH
- Incidence MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Pneumococcal Vaccines pharmacology MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Serogroup MeSH
- Streptococcus pneumoniae immunology MeSH
- Vaccination methods MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or PCV13 programmes on invasive pneumococcal disease (IPD) in older adults across 13 sites in 10 European countries, to support decision-making on pneumococcal vaccination policies. METHODS: For each site we calculated IPD incidence rate ratios (IRR) in people aged ≥65 years by serotype for each PCV10/13 year (2011-2015) compared with 2009 (pre-PCV10/13). We calculated pooled IRR and 95% CI using random-effects meta-analysis and PCV10/13 effect as (1 - IRR)*100. RESULTS: After five PCV10/13 years, the incidence of IPD caused by all types, PCV7 and additional PCV13 serotypes declined 9% (95% CI -4% to 19%), 77% (95% CI 67% to 84%) and 38% (95% CI 19% to 53%), respectively, while the incidence of non-PCV13 serotypes increased 63% (95% CI 39% to 91%). The incidence of serotypes included in PCV13 and not in PCV10 decreased 37% (95% CI 22% to 50%) in six PCV13 sites and increased by 50% (95% CI -8% to 146%) in the four sites using PCV10 (alone or with PCV13). In 2015, PCV13 serotypes represented 20-29% and 32-53% of IPD cases in PCV13 and PCV10 sites, respectively. CONCLUSION: Overall IPD incidence in older adults decreased moderately after five childhood PCV10/13 years in 13 European sites. Large declines in PCV10/13 serotype IPD, due to the indirect effect of childhood vaccination, were countered by increases in non-PCV13 IPD, but these declines varied according to the childhood vaccine used. Decision-making on pneumococcal vaccination for older adults must consider the indirect effects of childhood PCV programmes. Sustained monitoring of IPD epidemiology is imperative.
EpiConcept Paris France Antwerp University Antwerp Belgium
European Centre for Disease Prevention and Control Stockholm Sweden
General Directorate of Public Health Madrid Spain
Health Protection Scotland National Services Scotland Glasgow UK
Health Protection Surveillance Centre Dublin Ireland
Irish Pneumococcal Reference Laboratory Temple Street Children's University Hospital Dublin Ireland
National Centre for Pneumococci European Hospital George Pompidou Paris France
National Institute for Health and Welfare Helsinki Finland
National Institute for Health and Welfare Helsinki Finland University of Tampere Tampere Finland
National Institute for Public Health and the Environment Bilthoven The Netherlands
National Institute of Public Health Prague Czech Republic
Norwegian Institute of Public Health Oslo Norway
Public Health Agency of Catalunya Barcelona Spain CIBER Epidemiología y Salud Pública Madrid Spain
Public Health Agency of Sweden Solna Sweden
Public Health England London UK
Santé publique France Saint Maurice France
Scottish Haemophilus Legionella Meningococcus and Pneumococcus Reference Laboratory Glasgow UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045174
- 003
- CZ-PrNML
- 005
- 20200120102528.0
- 007
- ta
- 008
- 200109s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/thoraxjnl-2018-211767 $2 doi
- 035 __
- $a (PubMed)30355641
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Hanquet, Germaine $u EpiConcept, Paris, France. Antwerp University, Antwerp, Belgium.
- 245 10
- $a Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination / $c G. Hanquet, P. Krizova, P. Valentiner-Branth, SN. Ladhani, JP. Nuorti, A. Lepoutre, J. Mereckiene, M. Knol, BA. Winje, P. Ciruela, M. Ordobas, M. Guevara, E. McDonald, E. Morfeldt, J. Kozakova, HC. Slotved, NK. Fry, H. Rinta-Kokko, E. Varon, M. Corcoran, A. van der Ende, DF. Vestrheim, C. Munoz-Almagro, P. Latasa, J. Castilla, A. Smith, B. Henriques-Normark, R. Whittaker, L. Pastore Celentano, C. Savulescu, SpIDnet/I-MOVE+ Pneumo Group,
- 520 9_
- $a BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or PCV13 programmes on invasive pneumococcal disease (IPD) in older adults across 13 sites in 10 European countries, to support decision-making on pneumococcal vaccination policies. METHODS: For each site we calculated IPD incidence rate ratios (IRR) in people aged ≥65 years by serotype for each PCV10/13 year (2011-2015) compared with 2009 (pre-PCV10/13). We calculated pooled IRR and 95% CI using random-effects meta-analysis and PCV10/13 effect as (1 - IRR)*100. RESULTS: After five PCV10/13 years, the incidence of IPD caused by all types, PCV7 and additional PCV13 serotypes declined 9% (95% CI -4% to 19%), 77% (95% CI 67% to 84%) and 38% (95% CI 19% to 53%), respectively, while the incidence of non-PCV13 serotypes increased 63% (95% CI 39% to 91%). The incidence of serotypes included in PCV13 and not in PCV10 decreased 37% (95% CI 22% to 50%) in six PCV13 sites and increased by 50% (95% CI -8% to 146%) in the four sites using PCV10 (alone or with PCV13). In 2015, PCV13 serotypes represented 20-29% and 32-53% of IPD cases in PCV13 and PCV10 sites, respectively. CONCLUSION: Overall IPD incidence in older adults decreased moderately after five childhood PCV10/13 years in 13 European sites. Large declines in PCV10/13 serotype IPD, due to the indirect effect of childhood vaccination, were countered by increases in non-PCV13 IPD, but these declines varied according to the childhood vaccine used. Decision-making on pneumococcal vaccination for older adults must consider the indirect effects of childhood PCV programmes. Sustained monitoring of IPD epidemiology is imperative.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a pneumokokové vakcíny $x farmakologie $7 D022242
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a séroskupina $7 D065288
- 650 _2
- $a Streptococcus pneumoniae $x imunologie $7 D013296
- 650 _2
- $a vakcinace $x metody $7 D014611
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Krizova, Pavla $u National Institute of Public Health, Prague, Czech Republic.
- 700 1_
- $a Valentiner-Branth, Palle $u Statens Serum Institut, Copenhagen, Denmark.
- 700 1_
- $a Ladhani, Shamez N $u Public Health England, London, UK.
- 700 1_
- $a Nuorti, J Pekka $u National Institute for Health and Welfare, Helsinki, Finland. University of Tampere, Tampere, Finland.
- 700 1_
- $a Lepoutre, Agnes $u Santé publique France, Saint-Maurice, France.
- 700 1_
- $a Mereckiene, Jolita $u Health Protection Surveillance Centre, Dublin, Ireland.
- 700 1_
- $a Knol, Mirjam $u National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
- 700 1_
- $a Winje, Brita A $u Norwegian Institute of Public Health, Oslo, Norway.
- 700 1_
- $a Ciruela, Pilar $u Public Health Agency of Catalunya, Barcelona, Spain. CIBER Epidemiología y Salud Pública, Madrid, Spain.
- 700 1_
- $a Ordobas, Maria $u General Directorate of Public Health, Madrid, Spain.
- 700 1_
- $a Guevara, Marcela $u CIBER Epidemiología y Salud Pública, Madrid, Spain. Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
- 700 1_
- $a McDonald, Eisin $u Health Protection Scotland, National Services Scotland, Glasgow, UK.
- 700 1_
- $a Morfeldt, Eva $u Public Health Agency of Sweden, Solna, Sweden.
- 700 1_
- $a Kozakova, Jana $u National Institute of Public Health, Prague, Czech Republic.
- 700 1_
- $a Slotved, Hans-Christian $u Statens Serum Institut, Copenhagen, Denmark.
- 700 1_
- $a Fry, Norman K $u Public Health England, London, UK.
- 700 1_
- $a Rinta-Kokko, Hanna $u National Institute for Health and Welfare, Helsinki, Finland.
- 700 1_
- $a Varon, Emmanuelle $u National Centre for Pneumococci, European Hospital George Pompidou, Paris, France.
- 700 1_
- $a Corcoran, Mary $u Irish Pneumococcal Reference Laboratory, Temple Street Children's University Hospital, Dublin, Ireland.
- 700 1_
- $a van der Ende, Arie $u Netherlands Reference Laboratory for Bacterial Meningitis, Academic Medical Centre, Amsterdam, The Netherlands.
- 700 1_
- $a Vestrheim, Didrik F $u Norwegian Institute of Public Health, Oslo, Norway.
- 700 1_
- $a Munoz-Almagro, Carmen $u CIBER Epidemiología y Salud Pública, Madrid, Spain. Instituto de Recerca Pediátrica, Hospital Sant Joan de Deu, Universitat Internacional de Catalunya, Barcelona, Spain.
- 700 1_
- $a Latasa, Pello $u General Directorate of Public Health, Madrid, Spain.
- 700 1_
- $a Castilla, Jesus $u CIBER Epidemiología y Salud Pública, Madrid, Spain. Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
- 700 1_
- $a Smith, Andrew $u Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory, Glasgow, UK.
- 700 1_
- $a Henriques-Normark, Birgitta $u Public Health Agency of Sweden, Solna, Sweden. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Whittaker, Robert $u European Centre for Disease Prevention and Control, Stockholm, Sweden.
- 700 1_
- $a Pastore Celentano, Lucia $u European Centre for Disease Prevention and Control, Stockholm, Sweden.
- 700 1_
- $a Savulescu, Camelia $u EpiConcept, Paris, France.
- 710 2_
- $a SpIDnet/I-MOVE+ Pneumo Group
- 773 0_
- $w MED00004515 $t Thorax $x 1468-3296 $g Roč. 74, č. 5 (2019), s. 473-482
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30355641 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200120102905 $b ABA008
- 999 __
- $a ok $b bmc $g 1483443 $s 1083847
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 74 $c 5 $d 473-482 $e 20181024 $i 1468-3296 $m Thorax $n Thorax $x MED00004515
- LZP __
- $a Pubmed-20200109
